To provide the basis for new diagnostic, therapeutic and vaccination strategies needed to control the present and future pandemics.

Short term: Development of therapeutic molecules by facilitating quality control methods.

Medium term: To define the humoral immune response of patients with COVID-19 (our body’s protective response to extracellular particles of the virus). Diagnosis and stratification of patients.

Long term: To define mechanisms associated with the infection process. New diagnostic and/or therapeutic routes.

Principal Investigator: Fernando Corrales (CNB)